Seattle-based vaccine company Icosavax posted disappointing clinical data today for its experimental COVID-19 vaccine, sending its stock into a dive.… Read More
Seattle-based biotech startup Icosavax today scored $51 million in funding to create vaccines from artificial viruses. The Series A financing… Read More